Scholarlink

Background and purpose <p>This study evaluated the incidence and clinical impact of radiation pneumonitis (RP) in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following concurrent chemoradiotherapy (CCRT), with a particular focus on durvalumab interruption, re-administration, and overall survival (OS).</p> Materials and methods <p>This retrospective study included patients treated at our institution between April 2018 and June 2024. Durvalumab was administered for up to one year or until discontinuation due to adverse events or disease progression. RP was graded according to CTCAE version 5.0. Associations between grade ≥ 2 RP and clinical or treatment-related factors were assessed using univariate and multivariate analyses. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models.</p> Results <p>Among 101 patients, 48 (47.5%) developed grade ≥ 2 RP (grade 2: 41.6%; grade 3: 4.0%; grade 4: 2.0%). Lung V20 &gt; 30% was independently associated with grade ≥ 2 RP. Durvalumab interruption occurred in a subset of patients with grade 2 RP; among these patients, 25 (59.5%) were able to undergo durvalumab re-administration, with RP recurrence observed in only one patient after re-administration. The 2-year and 3-year OS rates were 75.1% and 60.9%, respectively. Completion of durvalumab was the strongest independent predictor of OS (hazard ratio 0.14; <i>P</i> = 0.00007), whereas grade ≥ 2 RP itself was not significantly associated with OS.</p> Conclusions <p>In this real-world cohort, completion of durvalumab consolidation after CCRT was strongly associated with improved OS in patients with stage III NSCLC. Although grade ≥ 2 RP was a frequent complication, temporary interruption and re-administration were feasible in selected patients. However, these findings should be interpreted cautiously because of the retrospective design and potential residual confounding.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Shuri Aoki,
  • Ryo Ariyasu,
  • Tatsuya Kamima,
  • Yosuke Sato,
  • Kenji Tokumasu,
  • Wataru Anno,
  • Yasuhiro Ogura,
  • Masahiro Kaneko,
  • Mingyon Mun,
  • Hironori Ninomiya,
  • Makoto Nishio,
  • Yasuo Yoshioka

摘要

Background and purpose

This study evaluated the incidence and clinical impact of radiation pneumonitis (RP) in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following concurrent chemoradiotherapy (CCRT), with a particular focus on durvalumab interruption, re-administration, and overall survival (OS).

Materials and methods

This retrospective study included patients treated at our institution between April 2018 and June 2024. Durvalumab was administered for up to one year or until discontinuation due to adverse events or disease progression. RP was graded according to CTCAE version 5.0. Associations between grade ≥ 2 RP and clinical or treatment-related factors were assessed using univariate and multivariate analyses. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models.

Results

Among 101 patients, 48 (47.5%) developed grade ≥ 2 RP (grade 2: 41.6%; grade 3: 4.0%; grade 4: 2.0%). Lung V20 > 30% was independently associated with grade ≥ 2 RP. Durvalumab interruption occurred in a subset of patients with grade 2 RP; among these patients, 25 (59.5%) were able to undergo durvalumab re-administration, with RP recurrence observed in only one patient after re-administration. The 2-year and 3-year OS rates were 75.1% and 60.9%, respectively. Completion of durvalumab was the strongest independent predictor of OS (hazard ratio 0.14; P = 0.00007), whereas grade ≥ 2 RP itself was not significantly associated with OS.

Conclusions

In this real-world cohort, completion of durvalumab consolidation after CCRT was strongly associated with improved OS in patients with stage III NSCLC. Although grade ≥ 2 RP was a frequent complication, temporary interruption and re-administration were feasible in selected patients. However, these findings should be interpreted cautiously because of the retrospective design and potential residual confounding.